SarahChen_PharmD said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
That is the short version; the long version is somebody else's post.
One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.
CarlaRPh_TPA said:I do not accept that the fasting window is a minor inconvenience.
Adding the part of the answer the thread has not reached. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
Ask again with the specifics and you will get a better answer than this one.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
Reporting back.
I moved the tablet to the moment I wake up rather than trying to fit it around breakfast, and the difference in the following weeks was obvious. It was a timing problem, not a dose problem.